Report
Teaser, summary, work performed and final results
Periodic Reporting for period 1 - SEEVIX Phase-1 (Spidersilk fibers as scaffold for tissue engineering: skin regeneratin and wound healing)
Teaser
Seevix is a biotech company producing high strength spidersilk fibers, identical to natural fibers. Through recombinant DNA technologies, we are unique in our ability to replicate the natural process of spidersilk creation. We induce the natural self-assembly process of the...
Summary
Seevix is a biotech company producing high strength spidersilk fibers, identical to natural fibers. Through recombinant DNA technologies, we are unique in our ability to replicate the natural process of spidersilk creation. We induce the natural self-assembly process of the proteins composing the fibers, thereby directly generating actual spidersilk, and do not need to purify or artificially spin those proteins into fibers. Seevix targets medical applications where the combination of the fibers’ extraordinary properties and biocompatibility can radically improve existing products and provide solutions for unmet medical needs. Based on our SVX™ fiber technology, Seevix developed SVX™gro, a unique 3D cell culture scaffold that is biocompatible, non-toxic and has many beneficial effects on cell culture, promoting cell proliferation and function. The objective of this project was to assess whether our technology could tap into unmet medical needs in the wound care field. We hypothesized that due to our fibers’ mechanical benefits and biocompatibility, we could apply SVX to develop a scaffold-based skin substitute to support healing of chronic wounds and burns. These segments of the wound market cost society tens of billions of dollars each year. In addition, innovation in the market is slow and novel approaches are eagerly sought after.
Work performed
Seevix performed an initial market research and held discussions with surgeons to map unmet needs in the tissue engineering and wound care market. We analyzed the fit of Seevix’s scaffold technology to these needs. We studied the regulatory framework and reimbursement environment, and performed an extensive risk analysis considering the technological, operational and financial aspects for successful product launch. We have developed a risk mitigation plan, a detailed workplan up to launch and an improved business plan for execution.
Final results
We expect that our products will expedite skin graft availability, improve wound healing for patients, reducing the cost burden to the health system and improve handling of skin grafts for surgeons. In terms of employment, the project is expected to create a total of 36 FTEs between 2019-2024.
For more information and updates, visit www.seevix.com, or follow us on Twitter (@SeevixMS) or LinkedIn
Seevix’s commercially available product, SVX™gro, is a spidersilk based scaffold for 3D tissue culture, and forms the basis for our wound healing products.
Website & more info
More info: http://www.seevix.com.